Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.727
EU - Europa 7.726
AS - Asia 3.514
SA - Sud America 60
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 13
OC - Oceania 10
Totale 22.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.552
IE - Irlanda 1.754
SG - Singapore 1.641
RU - Federazione Russa 1.491
IT - Italia 1.454
DE - Germania 1.133
SE - Svezia 1.026
HK - Hong Kong 751
CN - Cina 649
GB - Regno Unito 230
IN - India 227
UA - Ucraina 185
CA - Canada 168
ID - Indonesia 115
FI - Finlandia 85
NL - Olanda 65
DK - Danimarca 53
FR - Francia 49
AT - Austria 44
VN - Vietnam 40
BR - Brasile 38
BE - Belgio 34
CZ - Repubblica Ceca 24
ES - Italia 23
TR - Turchia 19
PL - Polonia 15
IR - Iran 14
KR - Corea 14
EU - Europa 12
PT - Portogallo 11
JP - Giappone 10
RO - Romania 10
CH - Svizzera 8
CL - Cile 8
TW - Taiwan 8
EG - Egitto 7
AR - Argentina 6
AU - Australia 5
GR - Grecia 5
NO - Norvegia 5
CO - Colombia 4
LT - Lituania 4
MM - Myanmar 4
TH - Thailandia 4
BG - Bulgaria 3
EE - Estonia 3
MX - Messico 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
EC - Ecuador 2
LK - Sri Lanka 2
LY - Libia 2
MD - Moldavia 2
PA - Panama 2
PK - Pakistan 2
RS - Serbia 2
TO - Tonga 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
DZ - Algeria 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
LI - Liechtenstein 1
LU - Lussemburgo 1
ME - Montenegro 1
MU - Mauritius 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 22.065
Salva come PNG Salva come JPEG
Città #
Dublin 1.705
Singapore 1.403
Ann Arbor 1.271
Frankfurt am Main 941
Princeton 886
New York 742
Hong Kong 741
Ashburn 673
Fairfield 672
Chandler 662
Santa Clara 572
Woodbridge 462
Houston 439
Milan 357
Lawrence 327
Altamura 321
Wilmington 300
Cambridge 249
Seattle 241
Jacksonville 163
San Diego 160
Pune 156
Shanghai 155
Dearborn 143
Jakarta 115
Andover 89
Toronto 82
Rome 70
London 68
Nanjing 61
Beijing 56
Washington 54
Helsinki 41
Hangzhou 40
Los Angeles 40
Fremont 37
Guangzhou 36
Boardman 34
Vienna 34
Lachine 28
Chicago 25
Dallas 25
Ottawa 25
Brussels 23
Shenyang 23
Tianjin 22
Bergamo 20
Huizen 20
Cedar Knolls 18
Dong Ket 18
Kilburn 17
Esslingen am Neckar 15
Monza 15
Turin 15
Brno 14
Jinan 14
Lappeenranta 14
Naples 14
Norwalk 14
Boston 13
Manchester 12
Nanchang 12
San Mateo 12
Umeå 12
Catania 11
Falls Church 11
Modena 11
Nuremberg 11
Padova 11
São Paulo 11
Azzano San Paolo 10
Florence 10
Mountain View 10
Groningen 9
Mumbai 9
Zhengzhou 9
Bonndorf 8
Changsha 8
Hounslow 8
Munich 8
Bologna 7
Brescia 7
Central 7
Hebei 7
Hyderabad 7
Lisbon 7
Ningbo 7
Phoenix 7
Warsaw 7
Albignasego 6
Assago 6
Nürnberg 6
Odense 6
Olomouc 6
Paris 6
San Sebastiano al Vesuvio 6
Tappahannock 6
Bari 5
Carate Brianza 5
Genoa 5
Totale 15.319
Salva come PNG Salva come JPEG
Nome #
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 294
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 237
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 196
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 196
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 193
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 192
Health Related Quality of Life in the Major Liver Conditions 186
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 185
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 181
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 179
The impact of liver disease on the health-related quality of life 178
Health related quality of life in chronic liver diseases 177
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 176
High rates of 30-day mortality in patients with cirrhosis and COVID-19 174
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 172
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 171
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 170
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 170
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 168
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 163
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 162
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 161
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 158
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 154
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 154
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 153
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 152
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 152
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 150
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 149
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 148
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 146
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 144
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 142
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 138
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 136
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 135
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 133
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 131
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 130
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 130
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 127
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 124
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 123
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 122
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 119
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 113
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 111
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 109
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 107
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 107
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness 107
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 106
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 104
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 103
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using “on demand” Approach: A Single Center Experience 102
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 102
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 99
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 97
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 95
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 93
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 92
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 91
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 84
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 83
Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe 82
Citolisi e colestasi post-oltx per cirrosi HCV: l’enigma della diagnosi differenziale 81
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 80
The societal burden of chronic liver diseases: Results from the COME study 78
Bergamo and Covid-19: How the Dark Can Turn to Light 75
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 74
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 74
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 73
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using" on demand" Approach: A Single Center Experience 72
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 72
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 70
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 67
Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study 67
Evidence for biliary epithelial to mesenchymal transition in human cholangiocarcinoma 67
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 66
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 65
Aumento di alfafetoproteina in pazienti con cirrosi HBeAg+/HBVDNA+ con sieroconversione ad anti HBe, spontanea ed indotta da interferon, 65
The use of molecular assays in the management of viral hepatitis 64
Il nuovo immunodepressore FK 506 modula il danno acuto da D galattosamina nel ratto 64
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 64
Plasma fibronectin in acute and chronic liver diseases [FIBRONECTINA PLASMATICA NELLE EPATOPATIE ACUTE E CRONICHE. VALIDITA DELL'ANALISI QUANTITATIVA] 63
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 62
The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management 61
Prevalent use of Combined Prophylaxis of Hepatitis B after liver transplantation in Italy: Results of a national survey in a large cohort 61
Meet–Test–Treat for HCV management: patients’ and clinicians’ preferences in hospital and drug addiction services in Italy 61
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 61
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 61
Correction to: Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group (Hepatology International, (2020), 14, 6, (930-943), 10.1007/s12072-020-10091-5) 61
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 60
Calcio libero citoplasmatico e citotossicita' in epatociti sottoposti ad anossia 60
Hormonal treatment of hepatocellular carcinoma 60
EVIDENCE FOR EPITHELIAL-MESENCHYMAL TRANSITION IN HUMAN CHOLANGIOCARCINOMA 59
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 59
COMBINED "EN BLOC" LIVER-PANCREAS TRANSPLANTATION USING WHOLE SIZE AND SPLIT LIVER GRAFTS 59
Le epatiti croniche: inquadramento nosografico 59
Totale 11.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.629
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020639 0 0 0 0 0 0 163 111 132 96 95 42
2020/20211.419 61 62 158 134 123 123 134 162 120 118 79 145
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/20255.388 822 1.742 601 606 1.226 389 2 0 0 0 0 0
Totale 23.663